BioSpace News Archive

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’) today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.

Oxford Instruments Asylum Research announces the release of its new atomic force microscope package developed for battery research, the Cypher ES Battery Edition.

Aridis Pharmaceuticals, Inc. announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme stabilizer component of AT-GAA.

Patients diagnosed with platinum-resistant Ovarian Cancer (PROC) often face poor prognosis due to the limited treatment options.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells in regions of inflammation, today announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.

ELEVAI LABS, INC. is pleased to report a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program.

– RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced plans to participate in the upcoming Bank of America Healthcare Conference.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET.